Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-5214 in Palmar Hyperhidrosis
NCT04263623Phase 2Unknown
- Sponsor
- Atacama Therapeutics, Inc.
- Start
- Jan 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dexmecamylamine in palmar hyperhidrosis (PH) (3 arms), sponsored by Atacama Therapeutics, Inc. Primary endpoint: Reduction in Palmar Hyperhidrosis Impact Scale (PHIS) at Week 6. Status: unknown.
02
Drugs
dexmecamylamine
03
Conditions
palmar hyperhidrosis (PH)
Beyond the preview
Go deeper on NCT04263623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04263623.